Arrowhead Pharmaceuticals Stock Forecast, Price & News

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARWR stock has increased by 106.2% and is now trading at $58.88.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.06. The biotechnology company earned $27.38 million during the quarter, compared to analysts' expectations of $38.76 million. Arrowhead Pharmaceuticals had a negative net margin of 19.75% and a negative return on equity of 5.65%.
View Arrowhead Pharmaceuticals' earnings history.

11 analysts have issued 1-year price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $31.00 to $90.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $65.73 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals.

Some companies that are related to Arrowhead Pharmaceuticals include Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Myokardia (MYOK), Dr. Reddy's Laboratories (RDY) and Sarepta Therapeutics (SRPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.27%), Retirement Systems of Alabama (0.26%), Envestnet Asset Management Inc. (0.03%), Pacer Advisors Inc. (0.03%), State of Alaska Department of Revenue (0.02%) and Defender Capital LLC. (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, William D Waddill and Zhen Li.
View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Envestnet Asset Management Inc., Arden Trust Co, and State of Alaska Department of Revenue. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, and Patrick O'brien.
View insider buying and selling activity for Arrowhead Pharmaceuticals.

ARWR stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Pacer Advisors Inc., Defender Capital LLC., Nisa Investment Advisors LLC, and HighMark Wealth Management LLC.
View insider buying and selling activity for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $58.88.

Arrowhead Pharmaceuticals has a market capitalization of $6.02 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 134 workers across the globe.

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]